Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The expression of telomerase in approximately 85% of cancers and its absence in the majority of normal cells makes it an attractive target for cancer therapy. However the lag period between initiation of telomerase inhibition and growth arrest makes direct inhibition alone an insufficient method of treatment. However, telomerase inhibition has been shown to enhance cancer cell radiosensitivity. To investigate the strategy of simultaneously inhibiting telomerase while delivering targeted radionuclide therapy to cancer cells, 123I-radiolabeled inhibitors of telomerase were synthesized and their effects on cancer cell survival studied. An 123I-labeled analogue of the telomerase inhibitor MST-312 inhibited telomerase with an IC50 of 1.58 μM (MST-312 IC50: 0.23 μM). Clonogenic assays showed a dose dependant effect of 123I-MST-312 on cell survival in a telomerase positive cell line, MDA-MB-435.

Original publication

DOI

10.1016/j.ejmech.2016.09.028

Type

Journal article

Journal

Eur J Med Chem

Publication Date

05/01/2017

Volume

125

Pages

117 - 129

Keywords

Iodine-123, Targeted radionuclide therapy, Telomerase, Telomerase inhibitors, Antineoplastic Agents, Benzamides, Cell Line, Tumor, Cell Survival, Chemoradiotherapy, Dose-Response Relationship, Drug, Enzyme Inhibitors, Humans, Iodine Isotopes, Radiation Tolerance, Radioisotopes, Telomerase